中國蜀塔(08623.HK)預期中期溢利下降約650萬元
格隆匯8月6日丨中國蜀塔(08623.HK)宣佈,公司預期於截至2020年6月30日止6個月錄得溢利淨額相較上年同期將下降約人民幣650萬元。有關下降乃主要由於集團因COVID-19爆發而於2020年前六個月的收益下降;相較上年同期,政府補貼及補助下降,此乃由於上年同期接收一次性政府補貼及補助約人民幣560萬元,但該一次性政府補貼及補助並無於2020年前6個月提供,以及中國政府因COVID-19影響下於2020年第一季度延遲派付約人民幣250萬元政府補貼及補助;及於2020年前6個月因已於2019年12月終止氧化鋁代理服務安排而未錄得代理費收入(2019年前6個月:錄得約人民幣250萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.